Drug induced acute pancreatitis: Does it exist?

World Journal of Gastroenterology

Volumn 20, Issue 44, 2014, Pages 16529-16534

  Tenner, Scott ^a,b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Drug induced acute pancreatitis; Idiopathic acute pancreatitis

Indexed keywords

AZATHIOPRINE; DRUG; EXENDIN 4; MERCAPTOPURINE; ANTIDIABETIC AGENT; INCRETIN; PEPTIDE; VENOM;

ACUTE PANCREATITIS; ARTICLE; DRUG SURVEILLANCE PROGRAM; HUMAN; IDIOPATHIC DISEASE; META ANALYSIS (TOPIC); NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); ACUTE DISEASE; ANIMAL; CHEMICALLY INDUCED; DIAGNOSTIC ERROR; FOOD AND DRUG ADMINISTRATION; PANCREATITIS; PREDICTIVE VALUE; PREVENTION AND CONTROL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; UNITED STATES;

ACUTE DISEASE; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANIMALS; DIAGNOSTIC ERRORS; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; PANCREATITIS; PEPTIDES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VENOMS;

EID: 84918794719     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i44.16529     Document Type: Article

References (43)

1. van Brummelen SE, Venneman NG, van Erpecum KJ, Van-Berge-Elenegouwen GP. Acute idiopathic pancreatitis: does it really exist or is it a myth? Scand J Gastroenterol Suppl 2003; (239): 117-122 [PMID: 14743894]
2. Frossard JL, Steer ML, Pastor CM. Acute pancreatitis. Lancet 2008; 371: 143-152 [PMID: 18191686 DOI: 10.1016/S0140-6736(08)60107-5]
3. Al-Haddad M, Wallace MB. Diagnostic approach to patients with acute idiopathic and recurrent pancreatitis, what should be done? World J Gastroenterol 2008; 14:1007-1010 [PMID: 18286679 DOI: 10.3748/wjg.14.1007]
4. DiMagno MJ, Dimagno EP. Pancreas divisum does not cause pancreatitis, but associates with CFTR mutations. Am J Gastroenterol 2012; 107: 318-320 [PMID: 22306946 DOI: 10.1038/ ajg.2011.430]
5. Steinberg WM, Chari ST, Forsmark CE, Sherman S, Reber HA, Bradley EL, DiMagno E. Controversies in clinical pancreatology: management of acute idiopathic recurrent pancreatitis. Pancreas 2003; 27:103-117 [PMID: 12883257 DOI: 10.1097/00006676-20030 8000-00001]
6. Tenner S, Baillie J, DeWitt J, Vege SS. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol 2013; 108: 1400-115; 1416 [PMID: 23896955 DOI: 10.1038/ajg.2013.218]
7. Jain V, Pitchumoni CS. Gastrointestinal side effects of prescription medications in the older adult. J Clin Gastroenterol 2009; 43: 103-110 [PMID: 19142171 DOI: 10.1097/MCG.0b013e31818f9227]
8. Tenner S. Drug-induced acute pancreatitis: underdiagnosis and overdiagnosis. Dig Dis Sci 2010; 55: 2706-2708 [PMID: 20686844 DOI: 10.1007/S10620-010-1367-2]
9. Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S. Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol 2007; 5: 648-61; quiz 644 [PMID: 17395548 DOI: 10.1016/j.cgh.2006.11.023]
10. Girard M. Conclusiveness of rechallenge in the interpretation of adverse drug reactions. Br J Clin Pharmacol 1987; 23:73-79 [PMID: 3814464 DOI: 10.1111/j.1365-2125.1987.tb03011.x]
11. Tenner S. Isotretinoin and inflammatory bowel disease: trial lawyer misuse of science and FDA warnings. Am J Gastroenterol 2014; 109:570-571 [PMID: 24698863]
12. Federal Food, Drug, and Cosmetic Act, 21 U.S.C.A. 301-3991 (West 2013). Available from: URL: http://web2.westlaw.com/signon/default.wl?vr=2.0&fn=-top&rs=WLW14.10&bhcp=1
13. Irey NS. Diagnostic problems in drug-induced diseases. Ann Clin Lab Sci 1976; 6:272-277 [PMID: 942185]
14. Stricker BH, Psaty BM. Detection, verification, and quantification of adverse drug reactions. BMJ 2004; 329: 44-47 [PMID: 15231627 DOI: 10.1136/bmj.329.7456.44]
15. Venning GR. Identification of adverse reactions to new drugs. III: Alerting processes and early warning systems. Br Med J (Clin Res Ed) 1983; 286: 458-460 [PMID: 6401562 DOI: 10.1136/ bmj.286.6363.458]
16. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Available from: URL: http://www.fda.gov/Safety/MedWatch/default.htm
17. Struve CT. The FDA and the tort system: postmarketing surveillance, compensation, and the role of litigation. Yale J Health Policy Law Ethics 2005; 5: 587-669 [PMID: 16052895]
18. Food and Drug Administration Amendments Act of 2007, PL 110-85, September 27, 2007,121 Stat. 823. Available from: URL: http://web2.westlaw.com/signon/default.wl?vr=2.0&fn=-top &rs=WLW14.10&bhcp=1
19. Denker P, DiMarco P. Exenatide as a cause of acute pancreatitis. Diabetes Care 2008; 29: 471-472 [DOI: 10.2337/diacare.29.02.06. dc05-2043]
20. Drug Evaluation and Research. Division Director's Memo, Pancreatitis (June 18, 2009). Available from: URL: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2009/021919s000SumR. pdfat13
21. Girman CJ, Kou TD, Cai B, Alexander CM, O'Neill EA, Williams-Herman DE, Katz L. Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes Obes Metab 2010; 12: 766-771 [PMID: 20649628 DOI: 10.1111/j.1463-1326.2010.01231.x]
22. Smotkin J, Tenner S. Laboratory diagnostic tests in acute pancreatitis. J Clin Gastroenterol 2002; 34: 459-462 [PMID: 11907364 DOI: 10.1097/00004836-200204000-00018]
23. Steinberg WM. Comment: acute pancreatitis associated with liraglutide. Ann Pharmacother 2011; 45: 1169 [PMID: 21811002 DOI: 10.1345/aph.1P714a]
24. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011; 141: 150-156 [PMID: 21334333 DOI: 10.1053/j.gastro.2011.02.018]
25. Amylin, Lilly and Alkermes Submit Reply to FDA Complete Response Letter for BYDUREON™ (April 22, 2010). Available from: URL: http://newsroom.lilly.com/releasedetail. cfm?releaseid=462639
26. FDA, Amylin Pharmaceuticals, Inc., Bydureon, Highlights of Prescribing Information (Jan 2012). Available from: URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/ 022200s0001bl.pdf at 5,12,27
27. Complaint for Damages, Johnson v. Amylin Pharmaceuticals, 13CV1346 DMS NLS (S.D. Cal. filed June 10, 2013). Available from: URL: http://web2.westlaw.com/signon/default.wl?vr=2 .0&fn=-top&rs=WLW14.10&bhcp=1
28. Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, Rosebraugh C. Pancreatic safety of incretin-based drugs-FDA and EMA assessment. N Engl J Med 2014; 370: 794-797 [PMID: 24571751 DOI: 10.1056/NEJMpl314078]
29. Weed DL, Gorelic LS. The practice of causal inference in cancer epidemiology. Cancer Epidemiol Biomarkers Preu 1996; 5: 303-311 [PMID: 8722223]
30. Weed DL. Causal and Preventive Inference.In: Greenwald P, Kramer BS, Weed DL. Cancer Prevention and Control. Chapter 17. New York: Marcel Dekker, 1995:285-302
31. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965; 58: 295-300 [PMID: 14283879]
32. Goldman SA. Limitations and strengths of spontaneous reports data. Clin Eher 1998; 20 Suppl C: C40-C44 [PMID: 9915089 DOI: 10.1016/S0149-2918(98)80007-6]
33. Van Dieren JM, Hansen BE, Kuipers EJ, Nieuwenhuis EE, Van der Woude CJ. Meta-analysis: Inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2007; 26: 643-652 [PMID: 17697198 DOI: 10.1111/ j.1365-2036.2007.03412.x]
34. Floyd A, Pedersen L, Nielsen GL, Thorlacius-Ussing O, Sorensen HT. Risk of acute pancreatitis in users of azathioprine: a population-based case-control study. Am J Gastroenterol 2003; 98: 1305-1308 [PMID: 12818274 DOI: 10.1111/ j.1572-0241.2003.07459.x]
35. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302:981-987 [PMID: 6102739]
36. Haber CJ, Meitzer SJ, Present DH, Korelitz BI. Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterology 1986; 91: 982-986 [PMID: 2427386]
37. Grendell JH. Editorial: drug-induced acute pancreatitis: uncommon or commonplace? Am J Gastroenterol 2011; 106: 2189-2191 [PMID: 22138943 DOI: 10.1038/ajg.2011.307]
38. Mallory A, Kem F. Drug-induced pancreatitis: a critical review. Gastroenterology 1980; 78: 813-820 [PMID: 6986321]
39. Lowenfels AB, Maisonneuve P, Sullivan T. The changing character of acute pancreatitis: epidemiology, etiology, and prognosis. Curr Gastroenterol Rep 2009; 11: 97-103 [PMID: 19281696 DOI: 10.1007/s11894-009-0016-4]
40. Lambert JS, Seidlin M, Reichman RC, Plank CS, Laverty M, Morse GD, Knupp C, McLaren G, Pettinelli C, Valentine FT. 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med 1990; 322:1333-1340 [PMID: 2139173 DOI: 10.1056/NEJM199005103221901]
41. Maxson CJ, Greenfield SM, Turner JL. Acute pancreatitis as a common complication of 2',3'-dideoxyinosine therapy in the acquired immunodeficiency syndrome. Am J Gastroenterol 1992; 87:708-713 [PMID: 1590305]
42. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326 [PMID: 23992601 DOI: 10.1056/NEJMoa1307684]
43. Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract 2012; 98: 271-284 [PMID: 23010561 DOI: 10.1016/j.diabres.2012.09.008]